3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Thrombosis
2
Venous Thromboembolism
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Ischemic Stroke
1
Hypertension, Portal
1
Endometrial Neoplasms
1
Cancer-associated Thrombosis
1
Interventions
Dexamethasone
420
Lenalidomide
265
Cyclophosphamide
246
Bortezomib
242
Melphalan
192
Calcium Dobesilate
166
fludarabine phosphate
112
daratumumab
103
Peripheral Blood Stem Cell Transplantation
99
carfilzomib
92
Thalidomide
90
Filgrastim
88
Mycophenolic Acid
82
fludarabine
81
pomalidomide
80
Whole-Body Irradiation
80
Busulfan
74
Tacrolimus
71
Granulocyte Colony-Stimulating Factor
66
Cyclosporine
58
dexamethasone acetate
56
ixazomib
55
Antilymphocyte Serum
50
dexamethasone 21-phosphate
49
auricularum
44
isatuximab
40
Etoposide
39
Radiotherapy
36
Stem Cell Transplantation
34
Methotrexate
33
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Multiple Myeloma
×
Anticoagulants
×
Clear all
NCT00790842
2018-10-24
PrE1003
PrECOG, LLC.
Phase 1/2
Terminated
63 enrolled
14 charts